INTRANASAL MERS-CoV VACCINE

An intranasal Middle East respiratory syndrome coronavirus (MERS-CoV) vaccine, comprising:

• a polysorbate carrier,
• albumin,
• at least one preservative selected from the group consisting of thimerosal, merthiolate, and gentamicin,
• an aqueous buffer solution, and
• a polypeptide that comprises at least one receptor-binding domain, immunogenic fragment, or epitope of S1 polypeptide of MERS-CoV, at least one trimerization motif, and at least one ligand for CD40;
• wherein the at least one trimerization motif comprises the amino acid sequence of SEQ ID NO:
• 6;
• or
• wherein the CD40 ligand is human CD40L comprising the sequence of SEQ ID NO:
• 23 or a sequence that is at least 70% identical thereto, or a CD40-binding fragment thereof;
• or
• wherein the CD40 ligand is camelid or human CD40L comprising the sequence of SEQ ID NO:
• 25 or 27 or a sequence that is at least 70% identical thereto, or a CD40-binding fragment thereof.